Slide 1: Corporate Presentation
Corporate Presentation Biodesix is a leading diagnostics company, driven to improve clinical care and outcomes for patients August 2026
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral presentation have been prepared by Biodesix, Inc. ("Biodesix", “we” or the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise
Slide 3: Biodesix is a leading diagnostics solutions company: mission and vision
Biodesix is a leading diagnostics solutions company, driven to improve clinical care and outcomes for patients. MISSION VISION support clinical decisions to expedite personalized Our mission is to transform patient care We envision a world where patient diseases care and improve outcomes for patient
Slide 4: Revenues generated by two business lines
Biodesix revenues are generated by two business lines enabled by scientific, technological, regulatory, and commercial excellence. Lung Diagnostic Tests Development Services Supporting clinical decisions to expedite Enabling the world’s leading personalized care and improve outcomes for biopharmaceu
Slide 5: Key Capabilities, Offering and Path to Profitability
Key Capabilities Offering Path to Profitability Sales representatives Medicare covered 104 in the field in 2Q26 focused on lung 5 tests for lung – 3 with ADLT status 82% Q2 2026 industry- leading gross margins diagnostics NYS CLEP approvals $108- Maintained FY 2026 300+ Publications and presentation
Slide 6: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Maintained FY 2026 Revenue Guidance of $108-114M - Mid-point reflects 25% growth Total Lung Dx Devt Svcs Gross Net Revenues Revenues Revenues Margin Loss AEBITDA* Q2 2026 $26.9M $25.4M $1.5M 82% ($7.3M) ($3.2M) Year over +34% +42% (29%) +200 basis +37% +56% Year points i
Slide 7: Two highly-certified, technologically-advanced laboratories
Two highly-certified, technologically-advanced laboratories LOUISVILLE, CO DE SOTO, KS CLIA certified CLIA certified CAP accredited CAP accredited NYS CLEP certified: Clinical Chemistry (limited to NYS CLEP certified: Clinical Chemistry (limited to soluble tumor markers), Oncology - Molecular & solu
Slide 8: Lung Diagnostic Tests
Lung Diagnostic Tests Our Core Commercial Clinical Offering
Slide 9: What Drives Us: The Fight Against Lung Cancer
What Drives Us: The Fight Against Lung Cancer USA lung cancer deaths vs colorectal, breast, and prostate cancers combined 120,000 PROSTATE 1 in 18 People will be diagnosed with lung cancer in their lifetime 6% 90,000 5-year survival for patients diagnosed with BREAST metastatic lung cancer 60,000 LU
Slide 10: Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests
Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests Lung Diagnostics Test Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Nodule Risk Assessment Treatment Guidance Testing Identify actionable Identify actionable Identify a patient’s Identify likely Identify likely tumor mutatio
Slide 11: Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests
Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests Lung Diagnostics Test Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Nodule Risk Assessment Treatment Guidance Testing Identify actionable Identify actionable Identify a patient’s Identify likely Identify likely tumor mutatio
Slide 12: The Challenge in Lung Nodule Management
The Challenge in Lung Nodule Management Balancing CT Surveillance with Intervention The smaller the nodule at Procedures on benign diagnosis, the greater the nodules come at a cost overall 5-year survival3 Surveillance Intervention Majority of lung Diagnosing cancer earlier nodules are benign leads
Slide 13: Standard Lung Cancer Risk Assessment Has Led to Over- and Under-Treatment
Standard Lung Cancer Risk Assessment Has Led to Over- and Under-Treatment of Patients 62% 35% 17% of patients receiving of patients who of patients sent to CT biopsy as the sole underwent surgery had surveillance have diagnostic procedure benign nodules1 malignant nodules2 were benign1 1Silvestri GA
Slide 14: One Blood Draw, Two Tests that Reclassify Risk
One Blood Draw, Two Tests that Reclassify Risk to Help Reduce Uncertainty in Lung Nodule Management Assessed Risk of Lung Cancer High Risk or (>65%) Patient Chart ~10% of patients identifies likely Biopsy Surgery Clinical Profile malignant nodules with test results in one day • Age (≥40) • Any Smoki
Slide 15: Blood-Based Nodule Risk Assessment
Blood-Based Nodule Risk Assessment Ordered together - Run in sequence Rule-Out Test: Identifies patients with lung nodules that Rule-In Test: Identifies patients with lung nodules that are are likely benign likely malignant Proteins on an LC-MS platform from blood Autoantibody detection on an ELISA
Slide 16: Nodify Lung Test: Published Data Package
Nodify Lung® Test: Published Data Package 1 2 3 4 5 DISCOVERY ANALYTICAL VALIDATION CLINICAL VALIDATION CLINICAL UTILITY HEALTH ECONOMICS & OUTCOMES 2012 2010 2017 2023 2023 Chapman et al, Tumor Murray et al, Annals of Massion et al, Thoracic Oncology Pritchett et al, “ORACLE” Smith et al, ISPOR Bio
Slide 17: Lung Cancer Risk Assessment Before and After Use of Nodify Lung Testing
Lung Cancer Risk Assessment Before and After Use of Nodify Lung® Testing Biodesix Clinical Utility Review Tool – available for use in clinical consultation with physicians Pre- and Post-test risk of lung cancer for first 110,000 commercial Nodify CDT and Nodify XL2 tests. Same data displayed in scat
Slide 18: Phased targeting execution from launch
Phased targeting execution from launch Interventional Phase 1 Targets at Nodify Pulmonologists testing launch in 2020 Phase 2 Targets and Proceduralists starting in 2021 GOAL: Build KOLs - Secure Sub-group of ~2,000 endorsement for Nodify Lung, GOAL: Drive adoption with pulmonologists mobilize for r
Slide 19: Overview of Physician Targeting Strategy
Overview of Physician Targeting Strategy After a comprehensive review and pilot study, we reconfigured our sales team to continue calling on pulmonologists and their referring PCPs, expanding our commercial channel to the full spectrum of care Pulmonology Targeting Primary Care Targeting • Tiered ap
Slide 20: Territory-Based Sales Pods Accessing Concentrated Nodule Referral Network
Territory-Based Sales “Pods” Accessing Concentrated Nodule Referral Network Leveraging Support from Pulmonology Territories anchored by senior Pulmonology Sales pulmonology sales Consultant representative with complementary primary care sales representatives and associate sales representatives provi
Slide 21: Building the Market: Increasing Patient Access in Pulmonology and Primary Care
Building the Market: Increasing Patient Access in Pulmonology and Primary Care 2024 Breadth of Call Points in US: • ~14,000 pulmonologists • ~15,000 of the ~250K PCPs are active in lung health programs ~50% Managed by Primary Care ~50% Managed by Pulmonology tend to CT surveillance tend to intervene
Slide 22: Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests
Extensive Portfolio of Medicare-Covered Lung Diagnostic Tests Lung Diagnostics Test Portfolio Lung Cancer Risk Assessment Lung Cancer Diagnosis Nodule Risk Assessment Treatment Guidance Testing Identify actionable Identify actionable Identify a patient’s Identify likely Identify likely tumor mutatio
Slide 23: Therapeutic Guidance Testing Helps Identify the Right Treatment
Following Diagnosis, Therapeutic Guidance Testing Helps Identify the Right Treatment for the Right Patient as Quickly as Possible >60 treatments and combinations recommended by NCCN for patients with lung cancer4 ~ 225k 10.5 months 26 days patients diagnosed annually median overall survival of patie
Slide 24: Treatment Guidance Tests for All Stages of Lung Cancer
Treatment Guidance Tests for All Stages of Lung Cancer Early stage Advanced, metastatic, or Lung Cancer recurrent Lung Cancer Immune profiling test Immune profiling test 52-gene test Average turnaround time of 2-3 business days ©2026 Biodesix, Inc. All rights reserved. 24
Slide 25: Rapid Turnaround Blood-Based Tumor & Immune Profiling
Rapid Turnaround Blood-Based Tumor & Immune Profiling 5000 patients enrolled in INSIGHT1 prospective clinical utility study GeneStrat® ddPCR Test GeneStrat NGS® Test VeriStrat® Test Identifies blood-based, guideline Identifies blood-based, guideline Blood-based test identifies a chronic recommended
Slide 26: Product pipeline
Product pipeline For tests outside of lung commercial focus, plan to partner for commercial distribution Test Type Indication Utility Recent Presentations Risk of Recurrence Proteomic & Lung and other solid tumor types Likelihood of recurrence Memorial Sloan Kettering (ROR) & Molecular Genomic and r
Slide 27: Development Services
Development Services Biopharmaceutical companies, life sciences tools and diagnostics companies, & academic research institutions
Slide 28: Biodesix Development Services: discovery, test development, and clinical study testing
Biodesix Development Services: strategic and customized discovery, test development, and clinical study testing $8.5M in Development Services under contract Life Sciences Tools Companies & Select Highlights Biopharma Partnerships Academic Research Partners Top Proteomics Company1 Life Sciences Revie
Slide 29: Thank you
W biodesix: Thank you 29
Slide 30: Appendix
Appendix W biodesix:
Slide 31: Leadership Team
Leadership Team: Extensive Experience in Diagnostics, Pharma, MedTech, Radiomics, & Healthcare Economics Scott Hutton Robin Harper Cowie Kieran O’Kane Gary Pestano Brianna Phillips CEO CFO CCO CSO (PhD) VP RA | QA Michael Kammer James Jett Steve Springmeyer Niki Givens Jessica Olbricht Head of Radio
Slide 32: Board of Directors
Board of Directors: extensive MedTech, Pharma, and Diagnostics industry expertise John Patience Chairman Crabtree Partners LLC Scott Hutton President & CEO Hany Massarany Chair – Compensation Committee Jean Franchi Chair – Audit Committee Matt Strobeck, Ph.D. Chair – Nominations & Governance Committ
Slide 33: Intellectual Property Portfolio
Intellectual Property Portfolio >100 Issued Patents 13 Unique Registered and Filed Trademarks US and International Across 13 Countries Patent Subject Matter: Registered Marks: • VeriStrat® and Nodify® tests and their uses in non-small cell lung • Biodesix • Biodesix Logo and other diseases (e.g., br
Slide 34: In-office blood collection with Tasso+ capillary device
In-office blood collection with Tasso+ capillary device Single-use blood lancing device intended for obtaining capillary whole blood Impact to Lung samples from a patient’s upper arm Nodule Patient Care FDA Class II Lancet 510(k) cleared Improves patient access to Nodify Lung® testing in practices w